The western front of the United States Capitol in Washington, DC.

The AACR Annual Meeting 2017 took place April 1-5, 2017, in Washington, DC.

Inhibitor exhibits activity against hematologic malignancies

Researchers in the lab
Photo by Rhoda Baer
A dual kinase inhibitor is active against a range of hematologic malignancies, according to preclinical research. Investigators found that ASN002, a SYK/JAK inhibitor, exhibited “potent” antiproliferative activity in leukemia, lymphoma, and myeloma cell lines. ... [Read Article]

Cancer risk, burden expected to shift in HIV population

Cancer patient
receiving chemotherapy
Photo by Rhoda Baer
New research suggests HIV-positive adults in the US will see a shift in cancer risk and burden in the coming years. The study indicates that, through 2030, people living with HIV will see a decrease in AIDS-defining cancers, such as non-Hodgkin lymphoma (NHL) and Kaposi... [Read Article]

Disease burden impacts outcome of CAR T-cell therapy in B-ALL

Jae Park, MD
Results of a retrospective study suggest pretreatment disease burden impacts the outcome of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Patients who had minimal residual disease (MRD) prior to treatment had superior event-free and overall survival compared to patients who... [Read Article]

Drug may be new option for difficult-to-treat DLBCL, doc says

Micrograph showing DLBCL
Selinexor has demonstrated the potential to become a new oral treatment option for patients with difficult-to-treat diffuse large B-cell lymphoma (DLBCL), according to a presenter at the AACR Annual Meeting 2017. Interim results from the phase 2b SADAL study showed that selinexor produced a 28.6% overall response rate (ORR) .... [Read Article]

Extremely short and long telomeres linked to risk of leukemia

Chromosomes in red with
telomeres in green
Image by Claus Azzalin
Telomere length may predict cancer risk and could be a target for future therapies, according to research presented at the AACR Annual Meeting 2017. The study suggests that, overall, longer-than-expected telomeres are associated with an increased risk of cancer. ... [Read Article]

Inhibitor produces durable responses in rel/ref iNHL

Micrograph showing
follicular lymphoma
An investigational drug can produce durable responses and has a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL), according to researchers. The drug is copanlisib, an intravenous pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor. ... [Read Article]

Half of patients retain response to CAR T-cell therapy

Micrograph showing DLBCL
Roughly half of patients who responded to chimeric antigen receptor (CAR) T-cell therapy in the ZUMA-1 trial have retained that response at a median follow-up exceeding 8 months. The CAR T-cell therapy, axicabtagene ciloleucel (formerly KTE-C19), initially produced an objective response rate (ORR) of 82% in this trial of patients with... [Read Article]

New BTK inhibitor may overcome resistance in CLL

Micrograph showing CLL
Preclinical research suggests a second-generation BTK inhibitor may overcome the acquired resistance observed with its predecessor in patients with chronic lymphocytic leukemia (CLL). Investigators found the non-covalent BTK inhibitor SNS-062 was unaffected by the BTK C481S mutation, which confers resistance to the first-generation BTK inhibitor ibrutinib. ... [Read Article]